Identification | Back Directory | [Name]
Tucotuzumab Celmoleukin | [CAS]
339986-90-2 | [Synonyms]
Tucotuzumab Celmoleukin Research Grade Tucotuzumab (DHD17404) |
Hazard Information | Back Directory | [Uses]
Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule[1]. | [in vivo]
Tucotuzumab (75 μg; intratumoral injection; 5 daily of 15 μg (total dose of 75 μg), each in 50 μL PBS; on days 10 and 14) results in significantly greater tumor growth suppression and enhances survival[1]. Animal Model: | Female Balb/c mice bearing CT26-KS colon adenocarcinoma[1] | Dosage: | 75 μg | Administration: | Intratumoral injection; 5 daily of 15 μg (total dose of 75 μg), each in 50 μL PBS; on days 10 and 14 | Result: | Resulted in significantly greater tumor growth suppression and enhanced survival.
|
| [References]
[1] Erik E Johnson, et al. Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma. Clin Cancer Res. 2009 Aug 1;15(15):4875-84. DOI:10.1158/1078-0432.CCR-09-0110 |
|
Company Name: |
Biolab Reagents
|
Tel: |
18108604356 18108604356 |
Website: |
www.biolabreagent.com/ |
Company Name: |
Cell Sciences
|
Tel: |
9785721070 |
Website: |
www.cellsciences.com |
Company Name: |
Biorbyt Ltd.
|
Tel: |
+44 (0)1223 859 353 |
Website: |
www.biorbyt.com |
|